Related Experiment Video
Updated: May 10, 2026

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
Published on: September 14, 2013
Clostridium difficile infection associated with antituberculous agents in a patient with tuberculous pericarditis
Yi-Xuan Sun1, Yin-Tao Zhao, Li-Li Teng
1Department of Geriatric Medicine, East Hospital, Tongji University School of Medicine, China.
Abstract:
Clostridium difficile can cause pseudomembranous colitis (PMC). Antimicrobial agent exposure is a risk factor for Clostridium difficile-associated disease, whereas the use of antituberculous (anti-TB) agents is not. We herein report a case of PMC-associated with antituberculous therapy. A 63-year-old woman with tuberculous pericarditis treated with anti-TB agents was admitted for abdominal pain and diarrhea. On colonoscopy, mucoid exudate and yellowish plaque lesions were observed. The anti-TB agents were discontinued, and the patient was treated with metronidazole and clostridium butyricum. Her symptoms were relieved and did not recur when the anti-TB agents were restarted. In this report, we review the literature and discuss the pathogenesis, clinical manifestations, diagnosis and treatment of this case.
Insights
Antituberculous therapy can lead to pseudomembranous colitis (PMC), a condition typically linked to other antimicrobials. This case highlights a patient whose PMC resolved upon stopping anti-TB drugs and recurred upon restarting them.
Area of Science:
- Infectious Diseases
- Gastroenterology
- Pharmacology
Background:
- Clostridium difficile infection (CDI) commonly causes pseudomembranous colitis (PMC).
- Antimicrobial exposure is a known risk factor for CDI.
- Antituberculous (anti-TB) agents are generally not considered a risk factor for CDI.
Observation:
- A 63-year-old woman with tuberculous pericarditis developed abdominal pain and diarrhea during anti-TB therapy.
- Colonoscopy revealed characteristic findings of PMC, including mucoid exudate and yellowish plaques.
- Discontinuation of anti-TB agents led to symptom resolution.
Findings:
- The patient's PMC resolved after stopping anti-TB medication.
- Symptoms recurred upon reinitiation of anti-TB therapy, suggesting a causal link.
- Treatment with metronidazole and Clostridium butyricum was effective.
Implications:
- This case suggests a potential association between anti-TB therapy and PMC.
- Further research is warranted to explore the pathogenesis of anti-TB-associated CDI.
- Clinicians should consider CDI in patients on anti-TB treatment presenting with gastrointestinal symptoms.
Related Concept Videos
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pericarditis I: Introduction
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Endocarditis I: Introduction
